The synergistic combined effect of anemia with high plasma levels of B-type natriuretic peptide significantly predicts an enhanced risk for major adverse cardiac events

Heart and Vessels

Volumn 23, Issue 4, 2008, Pages 243-248

  Ueno, Hirofumi ^a   Nakayama, Masafumi ^a   Kojima, Sunao ^a   Kusuhara, Kenichi ^a   Nagayoshi, Yasuhiro ^a   Yamamuro, Megumi ^a   Nishijima, Tsunenori ^a   Usuku, Hiroki ^a   Kaikita, Kouichi ^a   Sumida, Hitoshi ^a   Yamabe, Hiroshige ^a   Sugiyama, Seigo ^a   Yoshimura, Michihiro ^b   Ogawa, Hisao ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anemia; B type natriuretic peptide; Clinical outcome; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; SPIRONOLACTONE;

ADULT; AGED; ANEMIA; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEART FAILURE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; VALVULAR HEART DISEASE;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HEMOGLOBINS; HUMANS; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 48449097687     PISSN: 09108327     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00380-007-1034-5     Document Type: Article

References (41)

1. Silverberg DS, Wexler D, Blum M, Schwartz D, Wollman Y, Iaina A (2003) Erythropoietin should be part of congestive heart failure management. Kidney Int Suppl:S40-S47
2. Silverberg DS, Wexler D, Blum M, Wollman Y, Schwartz D, Sheps D, Keren G, Iaina A (2004) The interaction between heart failure, renal failure and anemia - the cardio-renal anemia syndrome. Blood Purif 22:277-284
3. Silverberg DS, Wexler D, Iaina A (2004) The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J Nephrol 17:749-761
4. Wexler D, Silverberg D, Sheps D, Blum M, Keren G, Iaina A, Schwartz D (2004) Prevalence of anemia in patients admitted to hospital with a primary diagnosis of congestive heart failure. Int J Cardiol 96:79-87
5. Silverberg DS, Wexler D, Blum M, Iaina A, Sheps D, Keren G, Schwartz D (2005) Erythropoietin in heart failure. Semin Nephrol 25:397-403
6. Lindenfeld J (2005) Prevalence of anemia and effects on mortality in patients with heart failure. Am Heart J 149:391-401
7. Felker GM, Adams KF Jr., Gattis WA, O'Connor CM (2004) Anemia as a risk factor and therapeutic target in heart failure. J Am Coll Cardiol 44:959-66
8. Tang YD, Katz SD (2006) Anemia in chronic heart failure: Prevalence, etiology, clinical correlates, and treatment options. Circulation 113:2454-2461
9. Fukunaga T, Soejima H, Irie A, Sugamura K, Oe Y, Tanaka T, Kojima S, Sakamoto T, Yoshimura M, Nishimura Y, Ogawa H (2007) Expression of interferon-gamma and interleukin-4 production in CD4+ T cells in patients with chronic heart failure. Heart Vessels 22:178-183
10. Mark DB, Felker GM (2004) B-type natriuretic peptide - a biomarker for all seasons? N Engl J Med 350:718-720
11. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39:1780-1786
12. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ (2001) Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38:955-962
13. Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 107:223-225
14. Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB (2004) Anemia and its relationship to clinical outcome in heart failure. Circulation 110:149-154
15. Szachniewicz J, Petruk-Kowalczyk J, Majda J, Kaczmarek A, Reczuch K, Kalra PR, Piepoli MF, Anker SD, Banasiak W, Ponikowski P (2003) Anaemia is an independent predictor of poor outcome in patients with chronic heart failure. Int J Cardiol 90: 303-308
16. Kosiborod M, Smith GL, Radford MJ, Foody JM, Krumholz HM (2003) The prognostic importance of anemia in patients with heart failure. Am J Med 114:112-119
17. McClellan WM, Flanders WD, Langston RD, Jurkovitz C, Presley R (2002) Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J Am Soc Nephrol 13:1928-1936
18. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87:1402-1412
19. Yoshimura M, Yasue H, Okumura K, Ogawa H, Jougasaki M, Mukoyama M, Nakao K, Imura H (1993) Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 87:464-469
20. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M, Ogawa H, Okumura K, Mukoyama M, Nakao K (1994) Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 90:195-203
21. Yoshimura M, Yasue H, Morita E, Sakaino N, Jougasaki M, Kurose M, Mukoyama M, Saito Y, Nakao K, Imura H (1991) Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 84:1581-1588
22. Levin ER, Gardner DG, Samson WK (1998) Natriuretic peptides. N Engl J Med 339:321-328
23. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K (1995) Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 96:1280-1287
24. Morita E, Yasue H, Yoshimura M, Ogawa H, Jougasaki M, Matsumura T, Mukoyama M, Nakao K (1993) Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88:82-91
25. de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, Hall C, Cannon CP, Braunwald E (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345:1014-1021
26. Sumida H, Yasue H, Yoshimura M, Okumura K, Ogawa H, Kugiyama K, Matsuyama K, Kikuta K, Morita E, Nakao K (1995) Comparison of secretion pattern between A-type and B-type natriuretic peptides in patients with old myocardial infarction. J Am Coll Cardiol 25:1105-1110
27. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347:161-167
28. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Maeda Y, Fukai D, Ohnishi M, Sugimoto Y, Kinoshita M (1997) Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 96:509-516
29. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, Hlavin P, Maisel AS (2002) B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39:131-138
30. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M (1998) Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 135:825-832
31. Taniguchi R, Sato Y, Nishio Y, Kimura T, Kita T (2006) Measurements of baseline and follow-up concentrations of cardiac troponin-T and brain natriuretic peptide in patients with heart failure from various etiologies. Heart Vessels 21:344-349
32. Iversen PO, Woldbaek PR, Tonnessen T, Christensen G (2002) Decreased hematopoiesis in bone marrow of mice with congestive heart failure. Am J Physiol Regul Integr Comp Physiol 282:R166-172
33. Weiss G (2002) Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 16:87-96
34. Anker SD, Negassa A, Coats AJ, Afzal R, Poole-Wilson PA, Cohn JN, Yusuf S (2003) Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensinconverting-enzyme inhibitors: An observational study. Lancet 361:1077-1083
35. Herrlin B, Nyquist O, Sylven C (1991) Induction of a reduction in haemoglobin concentration by enalapril in stable, moderate heart failure: A double blind study. Br Heart J 66:199-205
36. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich C, Latini R, Cohn JN (2005) Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: Results from Val-HeFT. Circulation 112:1121-1127
37. Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, Herzog CA (2005) Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 45:391-399
38. van der Meer P, Lipsic E, Westenbrink BD, van de Wal RM, Schoemaker RG, Vellenga E, van Veldhuisen DJ, Voors AA, van Gilst WH (2005) Levels of hematopoiesis inhibitor N-acetyl-serylaspartyl-lysyl-proline partially explain the occurrence of anemia in heart failure. Circulation 112:1743-1747
39. Shono M, Yoshimura M, Nakayama M, Yamamuro M, Abe K, Suzuki S, Mizuno Y, Sugiyama S, Saito Y, Nakao K, Yasue H, Ogawa H (2007) Predominant effect of A-type natriuretic peptide on reduction of oxidative stress during the treatment of patients with heart failure. Circ J 1:1040-1046
40. MacIntyre K, Capewell S, Stewart S, Chalmers JW, Boyd J, Finlayson A, Redpath A, Pell JP, McMurray JJ (2000) Evidence of improving prognosis in heart failure: Trends in case fatality in 66 547 patients hospitalized between 1986 and 1995. Circulation 102:1126-1131
41. McAlister FA, Ezekowitz J, Tonelli M, Armstrong PW (2004) Renal insufficiency and heart failure: Prognostic and therapeutic implications from a prospective cohort study. Circulation 109: 1004-1009